What is the TIMI risk score?
The Thrombolysis in Myocardial Infarction (TIMI) risk score for unstable angina and non–ST-segment elevation myocardial infarction (NSTEMI) is a simple, bedside tool that assigns one point for each of seven binary clinical features present at evaluation. The total ranges from 0 to 7. Higher scores identify patients with a greater short-term burden of ischemic complications and need for urgent revascularization in the populations in which the score was derived.
The score does not replace clinical judgment, serial electrocardiography, repeat biomarker testing, imaging, or invasive strategy decisions. It is best understood as a structured checklist that encodes major determinants of early risk after presentation with suspected acute coronary syndrome (ACS) without persistent ST elevation.
Why risk stratification matters in UA and NSTEMI
Patients with UA/NSTEMI form a heterogeneous group. Some have relatively stable plaques and low early event rates with medical therapy and careful observation; others have ongoing ischemia, large biomarker release, or dynamic ECG changes and benefit from intensified monitoring, antithrombotic therapy, and often an early invasive evaluation. Risk scores help teams communicate prognosis, prioritize resources, and align decisions with guideline concepts—always in conjunction with the full clinical picture.
The TIMI score was developed from a controlled trial cohort and reflects early (approximately 14-day) outcomes that included death, recurrent myocardial infarction, and need for urgent revascularization, as defined in the original study framework. When you interpret the score today, keep in mind that contemporary practice (high-sensitivity troponins, more routine early invasive strategies, and refined antiplatelet and anticoagulant regimens) may shift absolute event rates compared with historical cohorts, even when relative risk gradients remain informative.
How the score is calculated
Each of the following criteria contributes exactly one point if present. There is no weighting: the final score is the count of positive criteria.
1. Age 65 years or older
Advanced age is associated with more extensive atherosclerosis, higher comorbidity burden, and greater vulnerability to complications. The TIMI score treats age as a single threshold at ≥65 years for one point.
2. Three or more coronary artery disease risk factors
This item bundles traditional atherosclerotic risk factors. In the original description, these included elements such as family history of coronary disease, hypertension, hyperlipidemia, diabetes mellitus, and current tobacco use. The intent is to flag patients with a heavy risk-factor profile that marks underlying coronary disease risk even when symptoms are new or atypical.
3. Known coronary artery disease with at least 50% stenosis
A point is assigned when there is prior objective evidence of obstructive coronary disease—typically ≥50% diameter stenosis on coronary angiography or a prior positive functional study suggesting ischemia in a distribution consistent with CAD. This identifies patients who already carry a diagnosis of flow-limiting disease and are at higher risk when they present with recurrent acute ischemic symptoms.
4. Aspirin use in the prior seven days
Recent aspirin exposure suggests either established cardiovascular risk or prior clinician concern for vascular disease. In the prognostic models from which the score derives, this variable also helps identify patients who may still experience recurrent events despite antiplatelet therapy—raising the index of suspicion for unstable plaque biology or inadequate platelet inhibition relative to the clinical scenario.
5. Two or more episodes of severe angina in the last 24 hours
Frequent, severe ischemic symptoms over a short interval imply active or unstable ischemia. This criterion focuses on symptomatic burden rather than biomarkers or ECG alone. Accurate application requires a careful history: character, timing, triggers, and response to rest or nitroglycerin.
6. ST-segment deviation of at least 0.5 mm
ST-segment changes—elevation or depression—on the presenting ECG reflect ongoing supply–demand imbalance or injury pattern. The TIMI rule uses a threshold of ≥0.5 mm in applicable leads. Dynamic serial ECGs remain essential because a single baseline tracing may underestimate evolving ischemia.
7. Elevated cardiac biomarkers
Positive troponin or CK-MB (above the assay’s upper reference limit for myocardial infarction in the original framework) indicates myocardial necrosis and places the patient in the MI spectrum. With modern high-sensitivity troponin assays, institutional cutoffs, serial testing protocols, and universal MI definitions, the practical meaning of “elevated” should follow local laboratory standards and guideline-based algorithms.
Interpreting the total score
Because each variable is worth one point, the total is an integer from 0 through 7. In the derivation cohorts, higher scores aligned with stepwise increases in the combined endpoint of death, recurrent MI, and urgent revascularization over roughly two weeks.
Commonly cited approximate event rates for that composite (for teaching and orientation, not as rigid thresholds for individual patients) group as follows:
| TIMI score | Approximate 14-day composite risk |
|---|---|
| 0–1 | ~5% |
| 2 | ~8% |
| 3 | ~13% |
| 4 | ~20% |
| 5 | ~26% |
| 6–7 | ~41% |
Many clinicians also think in bands: 0–2 as relatively lower short-term risk, 3–4 intermediate, and 5–7 higher risk—useful for triage and discussion, while recognizing overlap between adjacent scores.
Relationship to other tools and pathways
The TIMI score is one of several ACS risk models (for example, GRACE emphasizes physiology, renal function, and hemodynamic compromise with continuous variables; other scores target chest pain in the emergency department or bleeding risk). Scores can disagree in individual patients; discrepancies often highlight which dimensions of risk dominate—ischemic burden versus hemodynamic instability versus comorbidity.
Guideline-informed care for NSTEMI typically integrates recurrent symptoms, ECG changes, arrhythmia, hemodynamic instability, suspected mechanical complications, failed medical therapy, and high-risk score as factors favoring an invasive strategy on an urgent or early timeline. Lower-risk presentations may be managed with selective invasive evaluation after further risk refinement. The TIMI score can support those conversations but should not be the only input.
Limitations and practical cautions
- The score was validated in specific trial populations; transportability to every modern emergency department population is not guaranteed.
- It is intended for UA/NSTEMI, not for STEMI, and not for stable chronic angina without acute presentation.
- Biomarker and ECG items evolve with technology; apply definitions consistent with current assays and definitions of MI.
- The score does not estimate bleeding risk or net benefit of anticoagulation—pair it with bleeding-risk tools when antithrombotic intensity is debated.
- Special populations (pregnancy, advanced kidney failure, prior CABG with graft disease, recent PCI) may not be fully captured by the seven items alone.
Using this calculator responsibly
Enter each criterion only when it is clearly met by the chart, ECG, and laboratory data at the time of assessment. Re-evaluate the score if the patient’s condition changes—new ST shifts, rising troponin, or refractory pain should trigger escalation regardless of a previously low number.